Meissner, Julia http://orcid.org/0000-0003-1908-2096
Schmitt, Michael http://orcid.org/0000-0002-1579-1509
Andrulis, Mindaugas
Schweizer, Leonille
Dietrich, Sascha
Alber, Bettina
Harting, Inga
Kurz, Felix T.
Martens, Uwe M.
Ho, Anthony D.
Müller-Tidow, Carsten
Dreger, Peter http://orcid.org/0000-0002-7429-8570
Article History
Received: 12 April 2022
Revised: 28 May 2022
Accepted: 30 May 2022
First Online: 9 June 2022
Competing interests
: JM received travel support from BMS, MSD, and Takeda. PD consulted for AbbVie, Allogene Therapeutics, AstraZeneca, bluebird bio, Gilead, Janssen, Novartis, Riemser, and Roche and received compensation. He has received compensation as a member of the speakers bureau for AbbVie, AstraZeneca, Gilead, Novartis, and Riemser. UMM received travel support from Roche, Amgen, and Celgene. MS received research grants from Apogenix, Hexal, and Novartis, travel support from Hexal and Kite as well as financial support for educational activities and conferences from bluebird bio, BMS, Kite/Gilead, and Novartis. He has received compensation as a member of the scientific advisory board of MSD and GSK. He is Co-Founder and shareholder of TolerogenixX Ltd. MA, LS, SD, BA, IH, FTK, ADH, and CMT declare no potential competing interests.